Statements (36)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:administeredBy |
intramuscular injection
|
| gptkbp:alsoKnownAs |
gptkb:Ad5-nCoV
|
| gptkbp:antigen |
gptkb:SARS-CoV-2_spike_protein
|
| gptkbp:approvedBy |
gptkb:Argentina
gptkb:Chile gptkb:China gptkb:Ecuador gptkb:Hungary gptkb:Indonesia gptkb:Kyrgyzstan gptkb:Laos gptkb:Malaysia gptkb:Mexico gptkb:Moldova gptkb:Pakistan gptkb:Peru gptkb:Serbia gptkb:Togo gptkb:Uzbekistan gptkb:Venezuela gptkb:Zimbabwe February 2021 |
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:countryOfOrigin |
gptkb:China
|
| gptkbp:developedBy |
gptkb:CanSino_Biologics
|
| gptkbp:dosingRegimen |
single dose
|
| gptkbp:emergencyServices |
gptkb:World_Health_Organization
|
| https://www.w3.org/2000/01/rdf-schema#label |
Convidecia
|
| gptkbp:storage |
2–8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:type |
viral vector vaccine
|
| gptkbp:vectorFor |
gptkb:adenovirus_type_5
|
| gptkbp:WHOListing |
emergency use listing
|
| gptkbp:bfsParent |
gptkb:CanSino_COVID-19_vaccine
|
| gptkbp:bfsLayer |
5
|